ViaDerma, Inc. (VDRM) Stock Analysis

ViaDerma, Inc. (VDRM) Healthcare & Pipeline Overview

ViaDerma, Inc. is a specialty pharmaceutical company developing and marketing products like Vitastem, a topical antibiotic. Operating in the US, they license their technology in various therapeutic areas. With a high P/E ratio and focus on niche markets, ViaDerma seeks growth through product development and strategic partnerships in the competitive pharmaceutical landscape.

What Is the Investment Thesis for VDRM?

ViaDerma, Inc. presents a high-risk, high-reward investment profile. The company's focus on specialty pharmaceutical products, particularly Vitastem, offers potential in niche markets. A high P/E ratio of 143.71 suggests market anticipation of future earnings growth, while a low Beta of 0.15 indicates lower volatility compared to the broader market. Growth catalysts include successful development and commercialization of pipeline products, as well as strategic licensing agreements. Key risks include reliance on a single product (Vitastem), competition from established pharmaceutical companies, and the challenges of navigating the regulatory landscape. The company's small market capitalization of $0.00B underscores its vulnerability to market fluctuations and operational setbacks.

Based on FMP financials and quantitative analysis

VDRM Key Highlights

ViaDerma, Inc. operates as a specialty pharmaceutical company focusing on topical treatments.

• The company's lead product, Vitastem, is a tetracycline-based topical antibiotic used for various skin conditions.
• ViaDerma has a high P/E ratio of 143.71, suggesting potential growth expectations.
• The company boasts a gross margin of 100.0%, indicating efficient cost management in product sales.
• ViaDerma has a low Beta of 0.15, suggesting lower volatility compared to the market.

Who Are VDRM's Competitors?

VDRM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are VDRM's Key Strengths?

Specialized product focus on topical treatments.

• Proprietary formulation of Vitastem.
• Potential for high gross margins (currently at 100%).
• Licensing opportunities for its technology.

What Are VDRM's Weaknesses?

Reliance on a single product (Vitastem) for revenue.

• Small market capitalization, making it vulnerable to market fluctuations.
• Limited financial resources for extensive R&D and marketing.
• OTC market listing, implying higher risk and lower liquidity.

What Could Drive VDRM Stock Higher?

Potential FDA approval for new topical treatments in development.

• Expansion of Vitastem's market reach through strategic partnerships.
• Licensing agreements with other pharmaceutical companies.
• Positive clinical trial results for pipeline products.
• Potential acquisition or merger opportunities.

What Are the Key Risks for VDRM?

Financial-distress signal — its Altman Z-Score of -4.75 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-0.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Competition from established pharmaceutical companies with greater resources.
• Regulatory hurdles and approval delays for new products.
• Reliance on a single product (Vitastem) for revenue.
• Patent expiration risks for Vitastem.
• OTC market listing implies higher risk and lower liquidity.

What Are the Growth Opportunities for VDRM?

• Expansion of Vitastem's Market Reach: ViaDerma has the opportunity to expand the market reach of Vitastem through strategic partnerships and targeted marketing campaigns. By focusing on specific market segments, such as dermatology clinics and wound care centers, ViaDerma can increase Vitastem's sales and market share. Timeline: Ongoing.
• Development and Commercialization of New Products: ViaDerma's pipeline of products in development represents a significant growth opportunity. The company is targeting various therapeutic areas, including toenail fungal infections, diabetic amputations, and acne. Successful development and commercialization of these products would diversify ViaDerma's revenue streams and reduce its reliance on Vitastem. Timeline: 2-5 years.
• Licensing Agreements and Technology Transfer: ViaDerma can leverage its technology and expertise through licensing agreements with other pharmaceutical companies. This would generate revenue and expand the reach of its products and technologies. The market for pharmaceutical licensing is robust, with numerous companies seeking to acquire or license innovative technologies and products. By actively pursuing licensing opportunities, ViaDerma can unlock significant value from its intellectual property. Timeline: Ongoing.
• Strategic Acquisitions and Partnerships: ViaDerma can pursue strategic acquisitions and partnerships to expand its product portfolio, market reach, and technological capabilities. This would accelerate its growth and enhance its competitive position. The pharmaceutical industry is characterized by frequent mergers and acquisitions, with companies seeking to consolidate their market positions and acquire new technologies. By identifying and pursuing strategic opportunities, ViaDerma can create significant value for its shareholders. Timeline: 1-3 years.
• Expansion into International Markets: ViaDerma has the opportunity to expand its operations into international markets. This would increase its sales and market share, and diversify its revenue streams. The global pharmaceutical market is vast, with significant growth opportunities in emerging markets. By carefully selecting target markets and developing appropriate market entry strategies, ViaDerma can successfully expand its international presence. Timeline: 3-5 years.

What Are VDRM's Competitive Advantages?

• Proprietary formulations, particularly for Vitastem.
• Licensing agreements that generate recurring revenue.
• Focus on niche markets with less competition from major pharmaceutical companies.

What Does VDRM Do?

ViaDerma, Inc., established in 2007 and headquartered in Marina Del Rey, California, operates as a specialty pharmaceutical company in the United States. Originally named Décor Products International, Inc., the company rebranded to ViaDerma, Inc. in May 2014, signaling a strategic shift towards the pharmaceutical sector. The company focuses on the development, marketing, and licensing of pharmaceutical products, targeting various therapeutic areas. ViaDerma's flagship product, Vitastem, is a tetracycline-based topical antibiotic designed for treating cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. Beyond Vitastem, ViaDerma is actively engaged in developing a pipeline of products addressing conditions such as toenail fungal infections, diabetic amputations, acne, psoriasis, eczema, burns, anti-aging solutions, medical cannabis applications, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. The company's business model involves both direct marketing of its products and licensing its technology to other pharmaceutical companies, aiming to broaden its market reach and revenue streams.

What Products and Services Does VDRM Offer?

• Develops and markets pharmaceutical products.
• Licenses its technology to other pharmaceutical companies.
• Focuses on specialty pharmaceutical products.
• Markets Vitastem, a tetracycline-based topical antibiotic.
• Develops products for various therapeutic areas, including dermatology and wound care.
• Aims to address conditions such as acne, psoriasis, and eczema.

How Does VDRM Make Money?

• Develops and markets its own pharmaceutical products, such as Vitastem.
• Licenses its pharmaceutical technology to other companies for revenue.
• Focuses on niche markets within the pharmaceutical industry.

What Industry Does VDRM Operate In?

ViaDerma, Inc. operates within the specialty pharmaceutical industry, a segment characterized by its focus on niche markets and specialized treatments. The industry is driven by innovation, regulatory approvals, and market demand for targeted therapies. Competition is intense, with both large pharmaceutical companies and smaller, specialized players vying for market share. ViaDerma's success depends on its ability to develop and commercialize innovative products, secure regulatory approvals, and effectively compete in this dynamic landscape.

Who Are VDRM's Key Customers?

• Individuals seeking treatment for cuts, scrapes, wounds, infections, burns, acne, psoriasis, and eczema.
• Pharmaceutical companies licensing ViaDerma's technology.
• Healthcare providers recommending or prescribing ViaDerma's products.

Return on equity for ViaDerma, Inc. stands at -0.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.3%, showing how much profit it generates from its asset base. VDRM trades at a trailing price-to-earnings ratio of 143.71, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 0.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.10 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.7%, the inverse of the P/E and a quick read on earnings relative to price.

VDRM Revenue & Earnings Trend

In Q3 FY2024, VDRM generated $150K in top-line revenue, marking a sequential increase of 0.0%. The company recorded a net loss of $322K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare.

Company Profile

ViaDerma, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Christopher A Otiko. VDRM has traded publicly since 2014.

ViaDerma, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.75 places it in the distress zone, a signal of elevated financial risk.

VDRM Financials

VDRM Latest News

VDRM Analyst Consensus

VDRM MoonshotScore

ViaDerma, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources